Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01463072 · ClinicalTrials.gov registry record · Phase 2
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Carcinoma and Recurrent Breast Carcinoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT01463072 is a Phase 2 study of Metastatic Breast Carcinoma and Recurrent Breast Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 40 participants, below the 164-participant average among 32 other Metastatic Breast Carcinoma trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT01463072, a Phase 2 study of Metastatic Breast Carcinoma and Recurrent Breast Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies the side effects of nab-paclitaxel in treating older patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Nab-paclitaxel
Study Locations (4)
California
- City of Hope medical - Duarte
- City of Hope Antelope Valley - Lancaster
- City of Hope South Pasadena - South Pasadena
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-06-19 |
| Est. Completion | 2026-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01463072
The ClinicalTrials.gov registry entry for NCT01463072 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 32 other Metastatic Breast Carcinoma trials with a reported enrollment target (76% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Metastatic Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01463072 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Ohio.
Frequently Asked Questions
What is clinical trial NCT01463072 about?
NCT01463072 is a clinical study titled "Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer". This phase II trial studies the side effects of nab-paclitaxel in treating older patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work ...
What is the current status of trial NCT01463072?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-06-19. Estimated completion is 2026-05-18.
What conditions does trial NCT01463072 study?
This clinical trial studies the following conditions: Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7.
What interventions are being tested in trial NCT01463072?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01463072?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01463072 being conducted?
This trial has 4 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
RECRUITING · Phase 2
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
RECRUITING · Phase 2
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
RECRUITING · Phase 2
-
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.